Introduction
============

Botulinum neurotoxin (BoNT) is the active agent that causes the deadly condition botulism. It is expressed as a single polypeptide chain of approximately 150 kDa and is cleaved post-translationally to yield an active di-chain molecule held together by a single disulphide bond. The smaller 50 kDa light chain (LC) possesses a single zinc-endopeptidase domain whereas the larger 100 kDa heavy chain is comprised of two domains---a target cell receptor binding (H~C~) domain and a translocation (H~N~) domain ([@ref-30]; [@ref-25]). BoNTs are the most poisonous biological substances known to man and their remarkable toxicity is a result of their highly specific and modular mechanism of action. The toxins target neuronal cell membranes through the formation of a dual receptor binding complex ([@ref-25]) which allows for internalisation by endocytosis ([@ref-5]). The H~N~ domain then translocates the LC into the cytoplasm where it cleaves a specific SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein which consequently inhibits vesicle release. Many immunologically distinct BoNTs have been discovered over the years---serotypes /A through to /G; although, only serotypes /A, /B, /E and /F have been reported to cause botulism in humans ([@ref-4]). Each serotype can be further subdivided into different subtypes based on their amino acid sequence ([@ref-28]).

The BoNT H~C~ domain is responsible for targeting the toxin to a specific cell type and the specific receptors involved have been identified for most serotypes. For example, serotype /A binds to a glycosylated luminal domain of the synaptic vesicle 2 (SV2) protein, preferentially to the C isoform (SV2C) ([@ref-7]; [@ref-19]), as well as a ganglioside, namely GT1b ([@ref-29]; [@ref-36]; [@ref-31]). X-ray crystallography has revealed protein-backbone hydrogen-bond interactions between β-strands of the BoNT/A1 H~C~ and the fourth luminal domain of SV2C (SV2C-LD4), as well as electrostatic interactions between charged surfaces ([@ref-2]). This is supplemented by additional interactions with the N-linked glycans present on the native SV2 molecule---this network of glycan interactions is key for BoNT potency ([@ref-35]).

BoNTs have been exploited for therapeutic use in many neurological indications such as dystonia and overactive bladder ([@ref-8]). More recently, BoNTs have been re-engineered to target different cell types and treat specific clinical indications ([@ref-21]; [@ref-22])---these are known as targeted secretion inhibitors (TSIs). A detailed understanding of the structural aspects of the different BoNT subtypes will prove useful in identifying regions of variability that may help uncover conserved mechanisms of binding, which in turn will guide efforts in developing novel BoNT therapeutics. Therefore, high-resolution, three-dimensional structural analysis of naturally occurring BoNTs, their mosaics and subtypes, would be of great value. Of particular interest are the structural differences arising from sequence differences between subtypes.

Recently, a new bivalent strain of *Clostridium botulinum,* IBCA10-7060, was reported to produce BoNT/B2 and a previously unknown BoNT serotype---"BoNT/H" ([@ref-1]). This novel toxin is a mosaic molecule and is now more commonly referred to as BoNT/FA (as well as BoNT/HA) due to a LC similar to that of BoNT/F5, a H~N~ domain similar to that of BoNT/F1, and a H~C~ domain similar to that of BoNT/A1 ([@ref-20]; [@ref-15]; [@ref-17]). The crystal structure of the BoNT/FA binding domain was recently reported ([@ref-34]). Here, we present a new crystal structure of H~C~/FA at 1.95 Å resolution which reveals further structural information that is unresolved in the reported structure. Specifically, our structure reveals a loop previously unmodeled due to lack of density, which is of high importance, and we also observe a disulphide bond which was not present within the previous structure. To this end we have produced two crystal forms of H~C~/A1 (determined to 1.45 Å and 1.7 Å respectively) differing by the presence of this disulphide bond.

Materials and Methods
=====================

Cloning and constructs
----------------------

The genes encoding the binding domain of BoNT/A1 (H~C~/A1) and BoNT/FA (H~C~/FA) were provided by Ipsen Bioinnovation Ltd. Each was cloned into the pJ401 expression vector (DNA 2.0, Menlo Park, CA, USA) with an N-terminal 6× histidine tag using standard molecular biology techniques and confirmed by sequencing (Eurofins Genomics, Germany).

Protein expression
------------------

His~6~-H~C~/A1 and His~6~-H~C~/FA were expressed in *E. coli* strain BL21(DE3) (Novagen, Madison, WI, USA) using the following protocol. A glycerol stock was used to inoculate 100 mL TB medium containing 50 µg/mL kanamycin, and grown at 37 °C for 16 h. From this, 10 mL of culture was used to inoculate 1 L TB medium containing 50 µg/mL kanamycin and grown at 37 °C to an OD~600~ of 0.6. The temperature was reduced to 16 °C and the cells grown to an OD~600~ of 1.0 at which point 0.5 mM isopropyl-d-1-thiogalactopyranoside (IPTG) was added to induce expression. Cells were grown for an additional 16 h at 16 °C and then harvested by centrifugation at 4,000× g for 30 min.

Protein purification
--------------------

Expression cell pastes were resuspended in 0.5 M NaCl, 50 mM Tris--HCl pH 7.4, 20 mM imidazole and lysed using a Constant Systems cell disruptor at 20 kPSI. Cell debris were removed by centrifugation at 80,000× g for 30 min and the supernatant was filtered through a 0.22 µm membrane syringe filter. The clarified lysate was loaded onto a 5 mL HisTrap column (GE Healthcare, Little Chalfont, UK), washed, and the target protein eluted with 0.5 M imidazole. His~6~-H~C~/A1 and His~6~-H~C~/FA were further purified by SEC using a Superdex 200 16/60 column (GE Healthcare, Little Chalfont, UK) and 0.5 M NaCl, 50 mM Tris-HCl pH 7.4. Purified samples were concentrated to 10 mg/mL using a 10 kDa MWCO centrifugal filter (Millipore, Billerica, MA, USA).

Crystallography
---------------

Crystals of His~6~-H~C~/FA and His~6~-H~C~/A1 were grown at 16 °C using a 1:1 ratio of protein solution (10 mg/mL) to well solution using the sitting-drop vapour-diffusion method---4 M sodium formate, 0.1 M sodium acetate pH 5.5 for the former, and 0.1 M MIB pH 4.0, 25% w/v PEG 1500 for the latter. Crystals were soaked in cryoprotectant (equal volume of reservoir solution and 50% glycerol) before vitrification in liquid nitrogen. Complete datasets were collected on beamline I03 and I04, respectively, at the Diamond Light Source (Didcot, UK). Diffraction images were processed using DIALS ([@ref-14]) and scaled using AIMLESS ([@ref-10]) from the CCP4 suite ([@ref-33]). Data collection statistics are summarised in [Table 1](#table-1){ref-type="table"}. A combination of R~pim~ and CC~1/2~ value were used to determine the resolution cut-off of 1.95 Å and 1.45 Å, respectively. Phase information was determined by molecular replacement using PHASER ([@ref-23]) and a previous structure of H~C~/A1 (PDB: 2VUA; [@ref-31]) as the initial search model. Multiple rounds of structure refinement were performed by manual correction in COOT ([@ref-9]) followed by restrained refinement with REFMAC5 ([@ref-26]). Final validation was performed with MolProbity ([@ref-3]). Secondary structures were annotated using Stride ([@ref-11]) and figures were prepared using PyMol (Schrödinger, LLC, New York, NY, USA) and CCP4mg ([@ref-24]).
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###### Crystallographic data collection and refinement statistics.

![](peerj-06-4552-g005)

                             H~C~/FA                                                     H~C~/A1 (crystal form 1)                                    H~C~/A1 (crystal form 2)
  -------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Space Group                P422                                                        P2~1~2~1~2~1~                                               P2~1~
  Cell dimensions                                                                                                                                    
  *a, b, c* (Å)              118.0, 118.0, 173.8                                         39.8, 107.3, 107.6                                          61.4, 53.9, 62.7
  *α*, *β*, *γ* (°C)         90.0, 90.0, 90.0                                            90.0, 90.0, 90.0                                            90.0, 106.1, 90.0
  Resolution (Å)             24.40--1.95 (1.98--1.95)[^a^](#table-1fn1){ref-type="fn"}   24.10--1.45 (1.48--1.45)[^a^](#table-1fn1){ref-type="fn"}   60.24--1.80 (1.84--1.80)[^a^](#table-1fn1){ref-type="fn"}
  R~merge~ (%)               20.1 (168.6)[^a^](#table-1fn1){ref-type="fn"}               7.6 (69.2)[^a^](#table-1fn1){ref-type="fn"}                 14.2 (53.9)[^a^](#table-1fn1){ref-type="fn"}
  R~meas~ (%)                20.8 (176.0)[^a^](#table-1fn1){ref-type="fn"}               9.7 (92.0)[^a^](#table-1fn1){ref-type="fn"}                 15.0 (58.8)[^a^](#table-1fn1){ref-type="fn"}
  R~pim~ (%)                 5.6 (50.2)[^a^](#table-1fn1){ref-type="fn"}                 5.8 (60.1)[^a^](#table-1fn1){ref-type="fn"}                 4.6 (22.5)[^a^](#table-1fn1){ref-type="fn"}
  CC1/2                      0.999 (0.832)[^a^](#table-1fn1){ref-type="fn"}              0.997 (0.357)[^a^](#table-1fn1){ref-type="fn"}              0.962 (0.954)[^a^](#table-1fn1){ref-type="fn"}
  \<I/*σ*(I)\>               12.6 (2.3)[^a^](#table-1fn1){ref-type="fn"}                 6.9 (1.3)[^a^](#table-1fn1){ref-type="fn"}                  14.4 (3.7)[^a^](#table-1fn1){ref-type="fn"}
  Completeness (%)           100.0 (100.0)[^a^](#table-1fn1){ref-type="fn"}              95.3 (95.1)[^a^](#table-1fn1){ref-type="fn"}                98.6 (89.1)[^a^](#table-1fn1){ref-type="fn"}
  Multiplicity               26.0 (23.7)[^a^](#table-1fn1){ref-type="fn"}                3.3 (2.7)[^a^](#table-1fn1){ref-type="fn"}                  20.4 (11.7)[^a^](#table-1fn1){ref-type="fn"}
  R~work~ (%)                18.0                                                        17.6                                                        18.8
  R~free~ (%)                20.9                                                        22.1                                                        22.3
  No. of atoms                                                                                                                                       
  Protein                    6,907                                                       3,511                                                       3,263
  Water                      609                                                         421                                                         322
  RMSD bond length (Å)       0.007                                                       0.002                                                       0.005
  RMSD bond angle (°)        0.89                                                        0.44                                                        0.73
  Wilson B factor (Å^2^)     24.6                                                        15.9                                                        13.4
  Average B factors (Å^2^)                                                                                                                           
  Protein                    28.2, 30.0                                                  21.2                                                        22.5
  Solvent                    33.8                                                        34.1                                                        28.0
  Ramachandran plot                                                                                                                                  
  Favoured (%)               96.7                                                        96.3                                                        96.4
  Allowed (%)                3.4                                                         3.5                                                         3.6
  Disallowed (%)             0.0                                                         0.2                                                         0.0
  PDB code                   5MK8                                                        5MK6                                                        5MK7

**Notes.**

Values in parentheses are for the highest resolution shell.

Results and Discussion
======================

Crystal structure of BoNT/FA H~C~ domain
----------------------------------------

We identified crystallisation conditions which yielded crystals of H~C~/FA in space group P422, with two molecules related by non-crystallographic symmetry in the asymmetric unit. This is different to a recently reported structure, PDB: 5V38 ([@ref-34]) and reveals an important loop that is involved in receptor binding (average temperature factor (B-factor) 74 Å^2^). A high-multiplicity dataset was collected containing 360 degrees of data over 3,600 images. No significant radiation damage was observed over the course of data collection and thus all data were used. The CC~1/2~ value for the outer shell was 0.832, indicating there was still very usable data at this resolution ([@ref-10]). The overall structure of H~C~/FA is shown in [Fig. 1C](#fig-1){ref-type="fig"} and the crystallographic statistics are listed in [Table 1](#table-1){ref-type="table"}. As with all reported structures of the BoNT receptor binding domain, present is a characteristic β-jellyroll fold at the N-terminal half and a predominantly β-trefoil fold at the C-terminal half of the protein ([Figs. 1A](#fig-1){ref-type="fig"}--[1D](#fig-1){ref-type="fig"}). Both molecules in the asymmetric unit overlay well with a root mean square deviation (RMSD) value of 0.35 Å between all atoms. The B-factors for each chain are low overall (24.74 Å^2^ and 26.84 Å^2^ respectively) with a corresponding overall Wilson B-factor of 24.55 Å^2^. As expected, our structure is highly similar to PDB: 5V38 with an RMSD value for combinations of chains between structures ranges from 0.54 Å to 0.36 Å ([Fig. 1D](#fig-1){ref-type="fig"}). However, it further reveals the presence of a loop (R1261--R1268) that has been shown in other subtypes to be involved in ganglioside receptor binding ([Fig. 2A](#fig-2){ref-type="fig"}). Crystal packing has enabled neighbouring chains to interact directly with this loop, provide sufficient stabilisation to produce good electron density. [@ref-34] suggested that the lack of density was due to high flexibility, which is consistent with the high B-factors we observed in this region relative to the rest of the protein.

![Crystal structures of HC domains.\
(A) HC/A1 domain (crystal form 1, PDB: 5MK6), (B) HC/A1 domain (crystal form 2, PDB: 5MK7), (C) HC/FA domain (PDB: 5MK8), and (D) overlay with a different crystal form of HC/FA (PDB:5V38; [@ref-34]). The position of loop R1261--R1268 indicated with an ellipse. All structures represented as a ribbon diagram, generated using PyMol (Schrödinger, LLC, New York, NY, USA).](peerj-06-4552-g001){#fig-1}

![Ganglioside binding site.\
(A) Electron density from a composite omit map for HC/FA. The location of a disulphide bond is marked with an asterisk. (B) The equivalent loop from HC/A1 (2VU9) with GT1b shown in glycoblock representation. Map produced using Phenix package ([@ref-32]).](peerj-06-4552-g002){#fig-2}

![Location of Cys1235 and Cys1280 residues.\
(A) Cys1235 and Cys1280 are not covalently bound in the HC/A1 crystal form 1, (B) disulphide bond formation in crystal form 2 and (C) a similar disulphide bond is seen in the HC/FA crystal structure between equivalent cysteines. Composite OMIT maps were produced using Phenix ([@ref-32]). And are shown for each model at 1 σ. Figure generated using CCP4mg ([@ref-24]).](peerj-06-4552-g003){#fig-3}

The specific ganglioside receptor for BoNT/FA is not yet known; however, considering that GT1b binds with high affinity to BoNT/A1 ([Fig. 2B](#fig-2){ref-type="fig"}) and that H~C~/FA and H~C~/A1 are structurally very similar, we propose that BoNT/FA possesses a similar binding specificity. The overall conformation of this region is also similar to that of BoNT/A1 in complex with a ganglioside receptor ([Fig. 2](#fig-2){ref-type="fig"}). The detailed conformation of this loop is important for understanding receptor binding and our structure confirms that BoNT/FA could bind to gangliosides in a similar manner to BoNT/A. Proximate to the ganglioside binding region, we observe the presence of a disulphide bond between Cys1227 and Cys1272 ([Fig. 3C](#fig-3){ref-type="fig"}) which is also not present in the structure 5V38. The equivalent bond has been observed previously in some, but not all crystal structures of BoNT H~C~ Domains; therefore, it is uncertain what role, if any, it may have towards BoNT function.

Crystal structures of the BoNT/A1 binding domain
------------------------------------------------

We have identified a single crystallisation condition that produced two crystal forms of H~C~/A1---one possessed the equivalent disulphide bond whereas the other did not. Using 25% w/v PEG 1500 and 0.1 M MIB pH 4.0, H~C~/A1 crystallised into orthorhombic crystals with the space group P2~1~2~1~2~1~ (crystal form 1) that diffracted to a resolution of 1.45 Å. No disulphide bond was observed in this structure ([Fig. 1A](#fig-1){ref-type="fig"}). Instead, Cys1235 rotated away from the junction due to a backbone rotation, bringing the neighbouring Lys1236 toward Cys1280 ([Fig. 3A](#fig-3){ref-type="fig"}). This is consistent with previous H~C~/A1 structures either in complex with GT1b (PDB: 2VU9; [@ref-31]), SV2-LD (PDB: 4JRA, 5JLV; [@ref-2]; [@ref-35]) or in the apo form (PDB: 2VUA; [@ref-31]). Using the same conditions, monoclinic crystals were obtained six months later with the space group P2~1~ (crystal form 2) that diffracted to 1.8 Å resolution. Inspection of this structure ([Fig. 1B](#fig-1){ref-type="fig"}) revealed the presence of a disulphide bond between C1235 and C1280, the equivalent of which was also observed in our H~C~/FA crystal structure ([Figs. 3A](#fig-3){ref-type="fig"} and [3B](#fig-3){ref-type="fig"}) and in a full-length BoNT/A1 crystal structure (PDB: 3BTA; [@ref-18]). Our findings suggest that the crystallisation condition is not the only determinant as to whether the bond is present or not. The conservation of these cysteine residues across the BoNT sub-serotypes suggests they are very important ([Fig. 4](#fig-4){ref-type="fig"}); however, their precise function is unknown. Almost all BoNT subtypes that cause human botulism contain the two residues. They may be required for disulphide bond formation for structural stability or for efficient function of a nearby ganglioside-binding pocket. It must be noted that the expression system does not appear to select for reduced or non-reduced forms of these cysteine residues---each have been observed in different structures of BoNT/A purified from the native *Clostridium botulinum* ([@ref-13]; [@ref-31]; [@ref-12]; [@ref-16]; [@ref-27]; [@ref-2]; [@ref-34]; [@ref-6]).

![Amino acid sequence alignment of BoNT subtypes emphasising the strong conservation of two cysteine residues near the protein C-terminus.\
UniprotKB accession numbers---A1: [A5HZZ9](http://www.uniprot.org/uniprot/A5HZZ9), A2: [Q45894](http://www.uniprot.org/uniprot/Q45894), A3: [Q3LRX9](http://www.uniprot.org/uniprot/Q3LRX9), A4: [Q3LRX8](http://www.uniprot.org/uniprot/Q3LRX8), A5: [C1IPK2](http://www.uniprot.org/uniprot/C1IPK2), A6: [C9WWY7](http://www.uniprot.org/uniprot/C9WWY7), A7: [K4LN57](http://www.uniprot.org/uniprot/K4LN57), A8: [A0A0A7PDB7](http://www.uniprot.org/uniprot/A0A0A7PDB7), HA(FA): [WP_047402807](https://www.ncbi.nlm.nih.gov/nucleotide?term=WP˙047402807) \*, B1: [P10844](http://www.uniprot.org/uniprot/P10844), B2: [A0A0B4W2B0](http://www.uniprot.org/uniprot/A0A0B4W2B0), B3: [A2I2S2](http://www.uniprot.org/uniprot/A2I2S2), B4: [A2I2S4](http://www.uniprot.org/uniprot/A2I2S4), B5: [A0A0E1L271](http://www.uniprot.org/uniprot/A0A0E1L271), B6: [H3K0G8](http://www.uniprot.org/uniprot/H3K0G8), B7: [H9CNK9](http://www.uniprot.org/uniprot/H9CNK9), B8: [M9VUL2](http://www.uniprot.org/uniprot/M9VUL2), E1: [Q00496](http://www.uniprot.org/uniprot/Q00496), E2: [A2I2S6](http://www.uniprot.org/uniprot/A2I2S6), E3: [A0A076L133](http://www.uniprot.org/uniprot/A0A076L133), E4: [P30995](http://www.uniprot.org/uniprot/P30995), E5: [Q9K395](http://www.uniprot.org/uniprot/Q9K395), E6: [A8Y878](http://www.uniprot.org/uniprot/A8Y878), E7: [G8I2N7](http://www.uniprot.org/uniprot/G8I2N7), E8: [G8I2N8](http://www.uniprot.org/uniprot/G8I2N8), E9: [WP_017352936](https://www.ncbi.nlm.nih.gov/nucleotide?term=WP˙017352936) \*, E10: [A0A076JVL9](http://www.uniprot.org/uniprot/A0A076JVL9), E11: [A0A076K0B0](http://www.uniprot.org/uniprot/A0A076K0B0), E12: [A0A0A7RCR1](http://www.uniprot.org/uniprot/A0A0A7RCR1), F1: [A7GBG3](http://www.uniprot.org/uniprot/A7GBG3), F2: [Q9ZAJ5](http://www.uniprot.org/uniprot/Q9ZAJ5), F3: [D2KHR6](http://www.uniprot.org/uniprot/D2KHR6), F4: [D2KHQ8](http://www.uniprot.org/uniprot/D2KHQ8), F5: [D2KHQ9](http://www.uniprot.org/uniprot/D2KHQ9), F6: [D2KHS6](http://www.uniprot.org/uniprot/D2KHS6), F7: [D2KHS9](http://www.uniprot.org/uniprot/D2KHS9), F8: [WP_076177537](https://www.ncbi.nlm.nih.gov/nucleotide?term=WP˙076177537) \*, F9: [A0A1P8YWK9](http://www.uniprot.org/uniprot/A0A1P8YWK9), G: [Q60393](http://www.uniprot.org/uniprot/Q60393), X: [WP_045538952](https://www.ncbi.nlm.nih.gov/nucleotide?term=WP˙045538952) \* (\*indicates NCBI accession code where UniprotKB accession is not available).](peerj-06-4552-g004){#fig-4}

Conclusion
==========

The high-resolution crystal structures of the binding domains (H~C~) from BoNT/FA and BoNT/A1 are reported here. The former complements a recently published structure ([@ref-34]) and resolves a loop which is highly important for receptor binding. For the latter, two structures were determined from two crystal forms obtained from the same crystallisation condition. These H~C~/A1 structures differed from one another by the presence or absence of a disulphide bond. This bond was also observed in our structure of H~C~/FA. Considering their location near the ganglioside-binding pocket, and conservation across BoNT subtypes, the redox status of these conserved cysteines may have implications in BoNT stability and manufacture. Botulinum neurotoxins are used therapeutically for many indications and their production is currently from the native host *Clostridium botulinum*. However, considering the safety implications and the advent of engineered BoNT derivatives, such as TSIs, production from a recombinant source would be highly desirable. The importance of these two cysteine residues is being further investigated.
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BoNT/X

:   botulinum neurotoxin serotype X

BoNT/FA

:   botulinum neurotoxin hybrid of /F and /A serotypes

H~C~

:   receptor binding domain of BoNT

LC

:   light chain of BoNT, catalytic domain

H~N~

:   translocation domain of BoNT

SV2C

:   synaptic vesicle 2 protein, isoform C

TSI

:   targeted secretion inhibitor
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